Summary Hepatic arterial cannulation for regional chemotherapy was achieved in 121/134 (90.2%) of colorectal liver metastasis patients. The perioperative mortality (5.8%) was significantly greater (P = 0.004) in patients with > 1000 ml (5/22, 23%) compared with < 1000 ml (2/83, 2.4%) metastasis volume. Colorectal liver metastasis patients should be considered for regional chemotherapy before metastases become extensive.
Metastasis resection cures 5% of patients with colorectal liver metastases (Steele and Ravikumar, 1989) but for the rest, tumour growth produces abdominal pain and distension, jaundice and inferior vena caval compression, resulting in death at an average of 7 months from liver metastasis diagnosis (Wood, 1980; AllenMersh et al, 1994) . Continuous hepatic arterial floxuridine infusion prevents clinically significant liver metastasis growth in 70% of patients (Dworkin and Allen-Mersh 1991; Allen-Mersh et al, 1994) , and doubles survival compared with patients receiving symptom palliation (Piedbois et al, 1996) . Although the hepatic artery can be cannulated percutaneously by inserting a Seldinger wire via the axillary or femoral artery under fluoroscopy, longterm treatment has not been possible with this approach because of catheter dislodgement and misperfusion of adjacent structures (Cohen et al, 1983) . These difficulties can be avoided by direct insertion of the catheter at laparotomy, but the limited survival benefit of hepatic arterial floxuridine could be impaired by complications from open hepatic artery cannulation.
This study assessed the morbidity and mortality in colorectal liver metastasis patients undergoing hepatic arterial cannulation at laparotomy and identified patient-or disease-related characteristics that were associated with a complicated outcome.
MATERIALS AND METHODS
All colorectal liver metastasis patients undergoing hepatic arterial cannulation in one unit between March 1988 and January 1996 were assessed. All had unresectable liver metastases with no evidence of extrahepatic disease after primary tumour removal, on abdominal computerized tomography (CT) scan and chest radiograph.
Exclusion criteria were patient age > 75 years, Karnofsky performance < 60, serum bilirubin > 20 mmol 1-1 or ascites.
Liver metastasis volume was measured from CT scan (Dworkin et al, 1995a) . Any weight loss in the month before hepatic artery cannulation was noted. Serum liver function tests, albumin, creatinine and full blood count were measured before and after operation. Physical symptoms were assessed by the Rotterdam Symptom Checklist (De Haes et al, 1990 ) before and at monthly intervals after operation.
At laparotomy via a subcostal incision, an Infusaid (Infusaid, Norwood, MA, USA) arterial cannula was inserted into the gastroduodenal artery to lie at its junction with the common hepatic artery (Curley et al, 1993) . Additional arteries were ligated where there was aberrant hepatic arterial anatomy (Burke et al, 1995) . All operations were performed by one consultant surgeon. On the fifth post-operative day, patients commenced floxuridine (0.2 mg kg-' body weight day-') by continuous hepatic arterial infusion for a 14-day cycle that was repeated each month (Allen-Mersh et al, 1994) .
Assessment of the duration of hospital stay excluded patients dying in hospital within 30 days of operation.
RESULTS
A total of 134 colorectal liver metastasis patients underwent laparotomy for hepatic arterial cannulation.
Failed cannulation group
Thirteen patients (9.7%) underwent laparotomy without hepatic artery cannulation. Liver metastasis volume was significantly greater (MWU test, P = 0.012) in failed cannulation (median 1970 ml, interquartile range 643-3018 ml) compared with cannulation (374 ml, interquartile range 66-1000 ml) patients. Reasons for failed cannulation were inaccessibility of the hepatic artery owing to gross hepatic enlargement (five patients) or hepatic arterial encasement by involved hepatic nodes (eight patients). Twelve of these patients underwent portal vein cannulation via a mesenteric 3000- Five were in patients with > 1000 ml tumour volume who exhibited a syndrome of tachycardia, thrombocytopenia and liver and renal failure by the third post-operative day (Figure 1 ). The sixth patient (tumour volume 907 ml) died on the first post-operative night following hepatic arterial rupture that was thought to be caused by catheterization-induced intimal tear. The seventh patient (tumour volume 418 ml) died on the second post-operative night following an acute myocardial infarction. There was a significant increase (Fisher's test, P = 0.004) in perioperative mortality in patients with > 1000 ml metastasis volume (5/22, 23%) compared with < 1000 ml (2/83, 2.4%). Stratification by preoperative history of weight loss, serum albumin, serum alkaline phosphatase or performance status did not significantly identify high risk of perioperative death (Table 1) .
Morbidity
Ten patients (8.2%) developed post-operative complications: [tachycardia/thrombocytopenia/liver and renal function abnormalities (as in Figure 1 ), two; pneumonia, two; pump pocket infection, two; subphrenic abscess, one; pyrexia of unknown origin, one; pump pocket haematoma, one; and pseudomembranous colitis, one]. The post-operative stay was significantly longer (MWU test, P = 0.003) in complicated (median 19 days, interquartile range 11-34 days) compared with uncomplicated (median 12 days, interquartile range 9-15 days) patients. There was no significant difference in preoperative tumour volume, serum albumin, serum alkaline phosphatase, weight loss or performance status in patients developing complications compared with those who did not (Table 1 ).
Significant deterioration in Rotterdam Symptom Checklist physical symptom score was not detected between preoperative baseline and that during the first 3 post-operative months.
DISCUSSION
The perioperative mortality of open hepatic arterial cannulation in this study (5.8%) would have been reduced to 2.4%, if patients with > 1000 ml tumour volume (roughly 40% liver replacement) had been excluded. Although 50% of patients can expect a partial tumour response from hepatic arterial floxuridine (Dworkin et al, 1991) regardless of extent of disease, the higher perioperative mortality (23% vs 2.4%) and failed cannulation (27% vs 8.4%) rate in patients with more than compared with less than 1000 ml liver metastasis volume resulted in 39% of patients with extensive metastases either failing to have the hepatic artery cannulated or dying within a month of the procedure. The absence of a significant increase in morbidity in patients with > 1000 ml liver metastasis volume (Table 1) (Burke et al, 1995 (Chang et al, 1987) in which any hepatic node involvement at laparotomy was taken as a contraindication to hepatic arterial chemotherapy. A sensitive predictor that hepatic nodes will not be involved with disease is a node-negative primary colorectal tumour (Dworkin et al, 1995b ) but this has a low specificity, as hepatic nodes are uninvolved by liver metastases in 64% of nodepositive primary colorectal cancers. We have not found that CT scan predicts hepatic artery encasement by involved nodes, and there is no reliable non-invasive test of hepatic lymph node involvement.
The cause of the tachycardia, thrombocytopenia and liver and renal function abnormalities that preceded the deaths of five patients and occurred in two other patients with extensive metastases was not clear. The features were consistent with an acute sepsis syndrome (Dunn, 1994) , but there was no evidence of infection on blood culture or at autopsy. In addition, the post-operative white cell count was not significantly different in these patients compared with uncomplicated cases (Figure 1 ). These abnormalities might have been produced by release of inflammatory mediators from liver parenchyma (Jenkins and Williams, 1980) or liver metastases (Ueda et al, 1994) . Hepatic parenchymal volume is not reduced by colorectal liver metastases (Dworkin et al, 1 995a), and it is also possible that catheterization-induced hepatic arterial thrombosis resulted in parenchymal necrosis where portal venous flow was impeded by metastases (Martin et al, 1990) .
The median tumour volume at which metachronous colorectal liver metastases are diagnosed clinically is approximately 800 ml (Allen-Mersh et al, 1994) . Thus, if liver metastasis diagnosis after primary tumour resection relies on clinical examination, the interval between detection of metastases and unsuitability for open hepatic artery cannulation is less than one tumour volume doubling time (Allen-Mersh, 1991) . Patients at high risk of liver metastases, who are deemed potentially suitable for intrahepatic chemotherapy, should undergo regular liver imaging (Gunven et al, 1985) so that metastases are detected before symptoms and signs develop. This would offer the best opportunity both for metastasis resection (Steele and Ravikumar, 1989) and also for uncomplicated hepatic arterial cannulation to administer regional chemotherapy.
